Federal Circuit Urged to Reevaluate Reinstated Patent for Novartis’s Entresto by MSN Pharmaceuticals

MSN Pharmaceuticals has called upon the full Federal Circuit to reevaluate a previous decision that reversed the invalidation of a patent for Novartis Pharmaceuticals’ widely-used cardiovascular drug, Entresto. Originally, a Delaware federal judge deemed the patent invalid due to a lack of written description, but this ruling was later overturned by a panel. MSN Pharmaceuticals is arguing that the initial decision to invalidate should stand, contending that the panel’s reversal was inappropriate. The ongoing legal battle highlights the complexities involved in patent law, particularly in the pharmaceutical industry. For further details, access the full discussion of the case through Law360.